SHR-3167

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

T2DMType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

Jiangsu HengRui Medicine Co., Ltd.T2DM

Start: 2023-06-09End: 2024-04-28Target: 52Updated: 2023-10-11

Phase 2

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

CompletedNCT06688123

Jiangsu HengRui Medicine Co., Ltd.Type 2 Diabetes

Start: 2025-01-08End: 2026-04-22Updated: 2026-06-04

A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Active, not recruitingNCT07018453

Jiangsu HengRui Medicine Co., Ltd.Type 2 Diabetes Mellitus

Start: 2025-07-16End: 2026-05-31Updated: 2025-11-18